Kadcyla For Late-Stage Breast Cancer Approved By FDA

Kadcyla (ado-trastuzumab emtansine), a new medication for the treatment of HER2-positive, metastatic breast cancer, has been approved by the Food and Drug Administration (FDA), USA. Metastatic, also known as late-stage, means the cancer has spread to other parts of the body. HER2, a protein which drives normal cell growth, is found in larger quantities in several kinds of cancer cells (HER2-positive), including a number of breast cancers. The HER2 protein contributes to the growth and survival of cancer cells in patients with HER2-positive breast cancer...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news